Great Point Partners’s Cymabay Therapeutics CBAY Stock Holding History

Great Point Partners’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-507,500	Closed	-$4.43M	–	55
2023 Q1	$4.43M	Sell	507,500 -1,042,500	-67%	-$8.35M	0.87%	28
2022 Q4	$9.72M	Buy	1,550,000 +750,561	+94%	+$2.85M	1.9%	22
2022 Q3	$2.8M	Buy	+799,439	New	+$2.87M	0.67%	32
2019 Q2	–	Sell	-998,841	Closed	-$13.3M	–	43
2019 Q1	$13.3M	Sell	998,841 -419,648	-30%	-$4.46M	1.31%	23
2018 Q4	$11.2M	Buy	+1,418,489	New	+$13.5M	1.41%	23

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Great Point Partners's CBAY Position: Q2 2023 in Review

Great Point Partners sold out of Cymabay Therapeutics (CBAY) in Q2 2023, closing a stake of 507,500 shares — an estimated $4.43M sold.

Great Point Partners first reported a position in CBAY in Q4 2018 and held it in 5 quarters. The position peaked at $13.3M in Q1 2019. 151 funds tracked by Wall St. Rank hold CBAY as of Q2 2023.

Great Point Partners reported no remaining Cymabay Therapeutics position as of Q2 2023 after selling out during the quarter.
Great Point Partners sold 507,500 Cymabay Therapeutics shares in Q2 2023, an estimated $4.43M.
Great Point Partners first reported a position in Cymabay Therapeutics in Q4 2018 and held it in 5 quarters.
Great Point Partners's Cymabay Therapeutics position peaked at $13.3M in Q1 2019.
151 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2023.

Based on Great Point Partners's 13F filing for Q2 2023, filed 14 Aug 2023.